David Johnson, PhD
Co-Director, Post Traumatic Stress Center, New Haven, CT
Research & Publications
Biography
News
Coauthors
Selected Publications
- Young lung cancer: Psychosocial needs assessment.Florez N, Kiel L, Horiguchi M, Kaufman R, Haradon D, Sanchez M, Lederman R, Voligny E, Nguyen T, McDonald S, Wilder F, Pozo-Kaderman C, Janne P, Johnson B, Partridge A, Enzinger A. Young lung cancer: Psychosocial needs assessment. Journal Of Clinical Oncology 2024, 42: 12104-12104. DOI: 10.1200/jco.2024.42.16_suppl.12104.
- Abstract PO1-14-10: Comprehensive clinicogenomic characterization of inflammatory breast cancerPriedigkeit N, Harrison B, Hughes M, Shue R, Li Y, Kirkner G, Remolano C, Strauss S, Files J, Feeney A, Mohammed-Abreu A, Garrido-Castro A, Barroso-Sousa R, Bychkovsky B, Nakhlis F, Bellon J, King T, Johnson B, Sholl L, Dillon D, Overmoyer B, Tolaney S, Cherniack A, Lin N, Lynce F. Abstract PO1-14-10: Comprehensive clinicogenomic characterization of inflammatory breast cancer. Cancer Research 2024, 84: po1-14-10-po1-14-10. DOI: 10.1158/1538-7445.sabcs23-po1-14-10.
- A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small-cell lung cancerRiely G, Smit E, Ahn M, Felip E, Ramalingam S, Tsao A, Johnson M, Gelsomino F, Esper R, Nadal E, Offin M, Provencio M, Clarke J, Hussein M, Otterson G, Dagogo-Jack I, Goldman J, Morgensztern D, Alcasid A, Usari T, Wissel P, Wilner K, Pathan N, Tonkovyd S, Johnson B. A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small-cell lung cancer. Future Oncology 2024, 20: 1047-1055. PMID: 38357801, DOI: 10.2217/fon-2023-0859.
- Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non–Small-Cell Lung Cancer: Results From the CANOPY-1 TrialTan D, Felip E, de Castro G, Solomon B, Greystoke A, Cho B, Cobo M, Kim T, Ganguly S, Carcereny E, Paz-Ares L, Bennouna J, Garassino M, Schenker M, Kim S, Brase J, Bury-Maynard D, Passos V, Deudon S, Dharan B, Song Y, Caparica R, Johnson B. Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non–Small-Cell Lung Cancer: Results From the CANOPY-1 Trial. Journal Of Clinical Oncology 2023, 42: 192-204. PMID: 38039427, DOI: 10.1200/jco.23.00980.
- P2.01-06 NAUTIKA1 Study: Preliminary Efficacy and Safety Data with Neoadjuvant Alectinib in Patients with Stage IB-III ALK+ NSCLCLee J, Toloza E, Pass H, Johnson B, Heymach J, Sholl L, Saqi A, Travis W, Wistuba I, Lin J, Kris M, Spira A, Shu C, Saltos A, Ding B, Schulze K, Zhu Q, Ngiam C, Bara I, Chaft J. P2.01-06 NAUTIKA1 Study: Preliminary Efficacy and Safety Data with Neoadjuvant Alectinib in Patients with Stage IB-III ALK+ NSCLC. Journal Of Thoracic Oncology 2023, 18: s297-s298. DOI: 10.1016/j.jtho.2023.09.511.
- MA20.06 Association of TTF-1 Expression with Outcomes to Immunotherapy and KRAS G12C Inhibition in Lung AdenocarcinomaDi Federico A, Ricciuti B, Alessi J, Pecci F, Lamberti G, Gandhi M, Vaz V, Voligny E, Nguyen T, Haradon D, Sholl L, Nishino M, Cooper A, Digumarthy S, Janne P, Heist R, Johnson B, Luo J, Awad M. MA20.06 Association of TTF-1 Expression with Outcomes to Immunotherapy and KRAS G12C Inhibition in Lung Adenocarcinoma. Journal Of Thoracic Oncology 2023, 18: s175. DOI: 10.1016/j.jtho.2023.09.264.
- P1.25-16 Outcomes by Age with Neoadjuvant Atezolizumab Treatment for Resectable Non-small Cell Lung Cancer in the Phase 2 LCMC3 StudyPresley C, Owen D, Nicholas A, Hilz S, Oezkan F, Chaft J, Toloza E, Haura E, Patterson A, Waqar S, Bunn P, Johnson B, Kris M, Lee J, Kwiatkowski D, Wistuba I, Schulze K, Johnson A, Rusch V, Carbone D. P1.25-16 Outcomes by Age with Neoadjuvant Atezolizumab Treatment for Resectable Non-small Cell Lung Cancer in the Phase 2 LCMC3 Study. Journal Of Thoracic Oncology 2023, 18: s275-s276. DOI: 10.1016/j.jtho.2023.09.470.
- P2.07-03 Factors Associated with Disease Progression after Discontinuation of Immunotherapy for Immune-Related Toxicity in Non-small Cell Lung CancerPecci F, Thummalapalli R, Alden S, Ricciuti B, Alessi J, Elkrief A, Rizvi H, Wang X, Egger J, Vaz V, Barrichello A, Lamberti G, Di Federico A, Gandhi M, Nishino M, Johnson B, Hellmann M, Schoenfeld A, Awad M. P2.07-03 Factors Associated with Disease Progression after Discontinuation of Immunotherapy for Immune-Related Toxicity in Non-small Cell Lung Cancer. Journal Of Thoracic Oncology 2023, 18: s323-s324. DOI: 10.1016/j.jtho.2023.09.561.
- 145MO Updated survival, efficacy and safety of adjuvant (adj) atezolizumab (atezo) after neoadjuvant (neoadj) atezo in the phase II LCMC3 studyCarbone D, Waqar S, Chaft J, Kris M, Johnson B, Lee J, Wistuba I, Kwiatkowski D, Bunn P, Schulze K, Johnson A, Brandao E, Awad M, Reckamp K, Chiang A, Nicholas A, Rusch V. 145MO Updated survival, efficacy and safety of adjuvant (adj) atezolizumab (atezo) after neoadjuvant (neoadj) atezo in the phase II LCMC3 study. Journal Of Thoracic Oncology 2023, 18: s90-s91. DOI: 10.1016/s1556-0864(23)00339-8.
- OA14.06 T-Cell Dynamics in Response to Neoadjuvant Atezolizumab in Early NSCLC by Antigen Response and T-Cell Receptor SequencingOezkan F, Hilz S, Grindheim J, Wallace A, Seweryn M, Reuben A, Zhang J, Owen D, Nicholas A, Yadav M, Nagarkar D, de Almeida P, Ebert P, Osborne E, Johnson A, Lee J, Bunn P, Johnson B, Chaft J, Kris M, Rusch V, Schulze K, Kwiatkowski D, Wistuba I, Carbone D. OA14.06 T-Cell Dynamics in Response to Neoadjuvant Atezolizumab in Early NSCLC by Antigen Response and T-Cell Receptor Sequencing. Journal Of Thoracic Oncology 2022, 17: s38-s39. DOI: 10.1016/j.jtho.2022.07.071.
- EP02.04-005 Phase II NAUTIKA1 Study of Targeted Therapies in Stage II-III NSCLC: Preliminary Data of Neoadjuvant Alectinib for ALK+ NSCLCLee J, Sepesi B, Toloza E, Lin J, Pass H, Johnson B, Heymach J, Johnson M, Ding B, Schulze K, Zhu Q, Ngiam C, Brandão E, Bara I, Chaft J. EP02.04-005 Phase II NAUTIKA1 Study of Targeted Therapies in Stage II-III NSCLC: Preliminary Data of Neoadjuvant Alectinib for ALK+ NSCLC. Journal Of Thoracic Oncology 2022, 17: s233-s234. DOI: 10.1016/j.jtho.2022.07.390.
- Abstract CT214: CANOPY-1: Safety run-in results from phase (ph) 3 study of canakinumab (CAN) or placebo (PBO) in combination (comb) with pembrolizumab (PEM) plus platinum-based doublet chemotherapy (Ctx) as 1st line therapy in patients (pts) with advanced or metastatic NSCLCJohnson B, Kim T, Hiltermann T, Barlesi F, Grohe C, Goto Y, Gunnarsson O, Overbeck T, Reguart N, Wermke M, Castro G, Felip E, Greystoke A, Solomon B, Deudon S, Louveau A, Passos V, Tan D. Abstract CT214: CANOPY-1: Safety run-in results from phase (ph) 3 study of canakinumab (CAN) or placebo (PBO) in combination (comb) with pembrolizumab (PEM) plus platinum-based doublet chemotherapy (Ctx) as 1st line therapy in patients (pts) with advanced or metastatic NSCLC. Cancer Research 2020, 80: ct214-ct214. DOI: 10.1158/1538-7445.am2020-ct214.
- The impact of the homecoming reception on the development of posttraumatic stress disorder: The West Haven Homecoming Stress Scale (WHHSS)Johnson D, Lubin H, Rosenheck R, Fontana A, Sonthwick S, Charney D. The impact of the homecoming reception on the development of posttraumatic stress disorder: The West Haven Homecoming Stress Scale (WHHSS). Journal Of Traumatic Stress 1997, 10: 259-277. DOI: 10.1002/jts.2490100207.
- The concept of the second generation program in the treatment of post-traumatic stress disorder among vietnam veteransJohnson D, Feldman S, Southwick S, Charney D. The concept of the second generation program in the treatment of post-traumatic stress disorder among vietnam veterans. Journal Of Traumatic Stress 1994, 7: 217-235. PMID: 8012744, DOI: 10.1007/bf02102945.